Carcinoma, Neuroendocrine - 23 Studies Found Not yet recruiting : Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas : High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) : 2017-04-18 : Drug: Pembrolizumab 200 mg eve Not yet recruiting : Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas : : 2024-11-23 Completed : KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors : Carcinoma, Neuroendocrine : 2014-08-21 : Drug: Selinexor Selective Inhibitor fo Nuclear Export (SINE) Recruiting : An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis : : 2024-11-23 Recruiting : A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours : : 2024-11-23 Recruiting : SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma : Small Cell Lung Cancer Large Cell Neuroendocrine Carcinoma : 2015-07-06 : Drug: SC-002 SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks Recruiting : Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin : Neuroendocrine Carcinomas : 2016-02-18 : Drug: cisplatinum and everolimus Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 o Recruiting : Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin : Neuroendocrine Carcinoma : 2016-02-17 : Drug: Everolimus Maintenance therapy Other Name: Afi Active, not recruiting : 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial : Neuroendocrine Carcinoma of the Lung and Thymus : 2012-03-20 : Drug: Pasireotide LAR 60 mg i. Not yet recruiting : Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes : Neuroendocrine Carcinoma, Grade 3 : 2017-05-08 : Drug: Avelumab Avelumab 10 mg/kg i.v. every 2 weeks (Q2W) <<< Previous | Next >>>
